Myriad Genetics, Inc. (NasdaqGS:MYGN) will look for acquisitions. At the First Quarter 2024 Earnings Conference Call, Paul Diaz, President and Chief Executive Officer said "I would say that both of the strategic transactions, we sort of are incorporating within the guide. And so and being able to reposition the portfolio with the additions of Precise Tumor and Precise Liquid, reorganize our European operations, become much more efficient in the way we were serving that market pretty extensively.

And to put a little more cash back on the balance sheet. So these are both very capital-efficient transactions and whether it's on the revenue or the profitability side, within our guidance for '24 and accretive to earnings and cash flow in '25. So we are really excited at this market and we are picking and choosing our opportunities, and we think there'll be more in terms of bolt-ons and strategic acquisitions going forward.

But those are the kind of stuff that we want to keep doing [indiscernible] or different philosophies around those kind of things".